Wire · operational-macro
Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdict
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Hansa Biopharma has submitted draft registration forms to the SEC for a potential Nasdaq listing in the U.S. while awaiting an FDA decision expected by December 19, 2026, on its kidney transplant drug imlifidase. The company has also sold regional development rights to strengthen finances ahead of a possible U.S. launch.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 21 Aug 2026 and 24 Aug 2026.
◆ ◆ The Wire takeaway
Your window to enter the US biotech market is opening with Nasdaq listing steps underway and FDA decisions due this year. Secure partnerships or capital now to position your launch when the transplant drug approval disrupts patient treatment options.
◆ Coverage
2 sources · first reported 21 Aug 2026 · latest 24 Aug 2026
◆ Related on Wire
◆ Topics